1. Home
  2. NGNE vs NKLR Comparison

NGNE vs NKLR Comparison

Compare NGNE & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.40

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

NKLR

Terra Innovatum Global N.V. Ordinary shares

HOLD

Current Price

$4.60

Market Cap

500.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
NKLR
Founded
2003
2018
Country
United States
Italy
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
498.2M
500.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
NKLR
Price
$35.40
$4.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$63.57
$15.00
AVG Volume (30 Days)
219.9K
282.8K
Earning Date
05-08-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$3.73
52 Week High
$37.27
$12.43

Technical Indicators

Market Signals
Indicator
NGNE
NKLR
Relative Strength Index (RSI) 68.81 39.11
Support Level $19.27 $3.99
Resistance Level $36.37 $5.25
Average True Range (ATR) 2.05 0.42
MACD 0.39 -0.01
Stochastic Oscillator 95.22 21.60

Price Performance

Historical Comparison
NGNE
NKLR

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

Share on Social Networks: